Study of JMT108 for Advanced Solid Tumors
Treatments studied
Part of Cancer, Digestive system, Skin clinical trials.
This trial tests a new drug called JMT108 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The study aims to see if the drug is safe and how it affects the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a confirmed advanced solid tumor that has spread or cannot be removed by surgery, and you have tried or cannot take standard treatments.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself most of the day (ECOG score of 0 to 2).
- Your expected survival is at least 3 months.
- You have not had active brain tumor spread or certain other treatments within the past few weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called JMT108 for people with advanced solid tumors that haven't responded to standard treatments. It aims to find out if the drug is safe and how well it works against cancer.
This study tests a new drug called JMT108 for advanced melanoma or urinary tract cancer. It may help your immune system attack the cancer, and the study is checking if it is safe and how well it works.
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
This trial tests a new investigational drug (JNJ-87890387) for people with certain advanced solid tumors that have spread or cannot be removed by surgery. It aims to see if the drug is safe and effective.
This study tests a new drug, KC1086, for people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The goal is to find out if KC1086 is safe and possibly effective, and it may be an option if you are physically active and your organs are healthy.
This early-stage trial tests whether a new drug called MST-168 can help people with advanced solid cancers (like lung, stomach, or colon cancer) that haven't responded to standard treatments. You'll receive the drug to see if it's safe and if it helps slow or stop your cancer.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.